Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Peng, Yuting; Zhang, Xiongze; Mi, Lan; Liu, Bing; Chen, Zuo; Wen, Feng; Wen, Feng

doi:10.1186/s12886-017-0481-8

Cited by 26 publications

(16 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been reported that conbercept is an effective treatment not only for patients with choroidal neovascularization secondary to punctate inner choroidopathy, 21 neovascular AMD, 22 macular edema secondary to branch retinal vein occlusion, 25 but also for patients with PCV. 23 In this retrospective study, treatment-naive PCV patients treated with conbercept using a “3+PRN” method over 6 months of follow-up visits resulted in a significant improvement in visual acuity and anatomical results.…”

Section: Discussionmentioning

confidence: 99%

“…Our previous study demonstrated that conbercept significantly improved visual and anatomical outcomes in choroidal neovascularization secondary to punctate inner choroidopathy. 21 Conbercept produced significant increases in best-corrected visual acuity (BCVA) and reductions in central retinal thickness (CRT) at 3 and 12 months of neovascular AMD. 22 In addition to visual improvement and a significant CRT decrease, a relatively high rate of polypoidal lesion resolution and/or branching vascular network (BVN) was observed in PCV patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy

Peng¹,

Zhang²,

Li³

et al. 2018

DDDT

Self Cite

View full text Add to dashboard Cite

IntroductionTo evaluate the functional and morphological outcomes of intravitreal conbercept monotherapy in patients with polypoidal choroidal vasculopathy (PCV).Materials and methodsIn this retrospective, observational case series study, we reviewed medical records of 48 eyes (48 patients) with naive PCV that were treated with a series of 3 monthly intravitreal injections of 0.5 mg of conbercept followed by as-needed injections (3+pro re nata). All patients completed at least 6 months of monthly follow-up. Changes in the best-corrected visual acuity, optical coherence tomography, and indocyanine green angiography were retrospectively evaluated.ResultsAt 6 months, the mean best-corrected visual acuity significantly improved from 0.89±0.35 (20/160 in Snellen equivalent) at baseline to 0.58±0.26 (Snellen equivalent of 20/80; P<0.001), and 60.42% (29/48) of eyes had an improvement of three lines of vision; the mean central retinal thickness significantly decreased from 333.56±171.04 μm at baseline to 187.65±54.46 μm (P<0.001), and 93.75% (45/48) achieved a dry macula. At 3 months, 6 of 32 eyes (18.75%) showed partial regression of branching vascular network, 14 of 32 (43.75%) patients showed complete resolution of polyps. The mean number of injections was 3.4±0.9 through 6 months. No conbercept-related systemic or ocular adverse effects were observed.ConclusionIntravitreal injection of conbercept using “3+pro re nata” regimen significantly improved visual acuity and anatomical outcomes in treatment-naive patients with PCV.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy

Peng¹,

Zhang²,

Li³

et al. 2018

DDDT

Self Cite

View full text Add to dashboard Cite

show abstract

“…Conbercept is similar in structure to aflibercept, an anti-VEGF agent that binds to all isoforms of VEGF-A, VEGF-B, and placental growth factor (PlGF); additionally, conbercept exhibits a higher affinity to VEGF because of the addition of the fourth Ig-like domain of VEGFR-2 in the Fab fragment. 11 …”

Section: Introductionmentioning

confidence: 99%

Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis

Wang¹,

Zhang²,

Hua³

2018

DDDT

View full text Add to dashboard Cite

IntroductionTo assess the ocular efficacy of intravitreal ranibizumab and conbercept injection in patients with neovascular age-related macular degeneration.Materials and methodsWe searched PubMed, Wed of Science, Cochrane Library, EMBASE, Google Scholar, Medline, China National Knowledge Infrastructure, and WANFANG DATA databases, up to June 20, 2018. We also searched abstracts and clinical study presentations at meetings as well as trial registries; we contacted authors of included studies if questions arose. Eligibility criteria for selection of studies were randomized controlled trials and retrospective trials that compared ranibizumab with conbercept for treatment of neovascular age-related macular degeneration.ResultsEight randomized controlled trials and four retrospective studies were included with a total of 853 patients. Best-corrected visual acuity after loading dosage was improved in the conbercept group, compared with the ranibizumab group (weighted mean difference: -0.04; 95% CI: -0.07 to 0.00; P=0.04). There was a significant difference between conbercept and ranibizumab therapy with respect to unchanged or recurrent leakage of choroidal neovascularization (OR: 0.46; 95% CI: 0.24–0.88; P=0.02). No significant differences were observed in central macular thickness (weighted mean difference: -2.92; 95% CI: -9.00 to 3.17; P=0.35), complete and partial closure of leakage of choroidal neovascularization (complete closure, P=0.70; partial closure, P=0.35), or number of injections (weighted mean difference: 0.42; 95% CI: -0.46 to 1.29; P=0.35) between the conbercept and ranibizumab groups at the end of the follow-up periods.ConclusionPooled evidence confirmed that conbercept was superior to ranibizumab with respect to visual gain after treatment. Additional studies with long-term follow-up are needed to support our conclusion.

show abstract

“…Similar to aflibercept in structure, conbercept could bind to all isoforms of VEGF-A, VEGF-B, and placental growth factor (PlGF). In addition, conbercept exhibits a higher affinity to VEGF due to the addition of the fourth Ig-like domain of VEGFR-2 in the Fab fragment [14]. Its affinity to VEGF is 50 times that of bevacizumab and 30 times that of ranibizumab [13,15].…”

Section: Introductionmentioning

confidence: 99%

Comparison of the Efficacy and Safety of Intravitreal Conbercept with Intravitreal Ranibizumab for Treatment of Diabetic Macular Edema: A Meta-Analysis

Sun

Zhang

Tian

et al. 2020

Journal of Ophthalmology

View full text Add to dashboard Cite

Introduction. This meta-analysis aimed to compare the therapeutic effect and safety of intravitreal conbercept (IVC) versus intravitreal ranibizumab (IVR) in treatment of diabetic macular edema (DME). Methods. Relevant studies were identified through systemic searches of PubMed, Embase, Cochrane Library, Ovid, CNKI, and Wanfang database up to 28 February 2019. Changes in central retinal thickness (CRT) in μm and best-corrected visual acuity (BCVA) in logMAR equivalents at 1, 3, and 6 months after initial treatment were performed by pooled analysis. Adverse events (AEs) were evaluated. Results. Eight articles involving 588 patients with DME were identified for this meta-analysis. The results showed that IVC significantly improved BCVA compared with IVR at 6 mo (SMD = −0.74 95% CI: −1.28 to −0.2; p=0.029) in patients with DME. IVC was superior to IVR in reducing central retinal thickness (CRT at 1 mo (p<0.0001), 3 mo (p=0.025), and 6 mo (p=0.019)) from baseline with statistical significance. For AEs, the pooled results showed that no significant difference in the risk of intraocular pressure increased (OR = 1.71; 95% CI: 0.55 to 5.25; p=0.352) or conjunctival hemorrhage (OR = 0.89; 95% CI: 0.34 to 2.34; p=0.65) between two groups. Conclusions. This meta-analysis showed that IVC trended to be more effective than IVR in terms of functional and anatomic outcomes for treating DME.

show abstract

Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Cited by 26 publications

References 30 publications

Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy

Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy

Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis

Comparison of the Efficacy and Safety of Intravitreal Conbercept with Intravitreal Ranibizumab for Treatment of Diabetic Macular Edema: A Meta-Analysis

Contact Info

Product

Resources

About